Fluticasone propionate
Based on 1 publication(s) in Google Scholar
Fluticasone propionate, a potent topical anti-inflammatory corticosteroid, is a selective glucocorticoid receptor agonist, with an absolute affinity (KD) of 0.5 nM. Fluticasone propionate shows little or no activity at other steroid receptors. Anti-viral activity.
Para uso exclusivo en investigación. No vendemos a pacientes.
- Pureza : 99.93%
- No. CAS: 80474-14-2
- Fòrmula: C25H31F3O5S
- Peso molecular:500.57
-
Almacenamiento:Powder -20°C, 3 years , 4°C, 2 years ; In solvent -80°C, 2 years , -20°C, 1 year
To place orders, for customer services and technical support, please contact: MedChemExpress USA
Tel: 609-228-6898 E-mail: [email protected] [email protected]
-
Actividad biológica
-
Chemical Information
-
Solvente y solubilidad
- Protocolo
- Pureza y Documentación
- Referencias
-
Help & FAQs
-
HY-13580
BudesonideGlucocorticoid Receptor Agonist -
HY-14648
DexamethasoneGR Agonist -
HY-13693
Mometasone furoateGlucocorticoid Receptor Agonist -
HY-B0636
Triamcinolone acetonideAnti-Inflammatory Agent -
HY-13683
MifepristoneProgesterone Receptor Antagonist -
HY-N0583
HydrocortisoneGlucocorticoid Receptor Agonist -
HY-B0625
CiclesonideGlucocorticoid -
HY-13600
Clobetasol propionateCYP3A5 Inhibitor -
HY-13570
BetamethasoneGlucocorticoid Receptor Agonist -
HY-15234
Fluticasone furoateNasal Spray -
HY-B0561
SpironolactoneAldosterone/Corticoid Receptor/Androgen Antagonists -
HY-B0260
MethylprednisoloneGlucocorticoid
Publications Citing Use of MedChemExpress (MCE) Fluticasone propionate
MoreVer todos los productos específicos de isoformas Endogenous Metabolite
MoreVer todos los productos específicos de isoformas ADC Payloads
More
Actividad biológica
Descripciòn
Cellular Effect
|
Cell Line
|
Type | Value | Description | References |
|---|---|---|---|---|
| HepG2 | EC50 |
0.7 nM
Compound: 3
|
Transactivation activity at glucocorticoid receptor in human HepG2 cells assessed as induction of tyrosine amino transferase
Transactivation activity at glucocorticoid receptor in human HepG2 cells assessed as induction of tyrosine amino transferase
|
[PMID: 21944381] |
| Neutrophil | ED50 |
3 μg
Compound: 1
|
Antiinflammatory activity in rat assessed as effective dose for inhibition of LPS-induced lung neutrophilia administered intratracheally 4 hr prior to LPS challenge
Antiinflammatory activity in rat assessed as effective dose for inhibition of LPS-induced lung neutrophilia administered intratracheally 4 hr prior to LPS challenge
|
[PMID: 21880489] |
| PBMC | IC50 |
0.1 nM
Compound: 1
|
Inhibition of TNFalpha release in human PBMC by ELISA assay
Inhibition of TNFalpha release in human PBMC by ELISA assay
|
[PMID: 21880489] |
| SW1353 | EC50 |
1.09 nM
Compound: 1
|
Agonist activity at GR in human SW1353 cells transfected with luciferase gene linked to MMTV promoter assessed as luciferase transactivation activity
Agonist activity at GR in human SW1353 cells transfected with luciferase gene linked to MMTV promoter assessed as luciferase transactivation activity
|
[PMID: 21880489] |
In Vitro
Fluticasone propionate inhibits TNFα-induced E-selectin expression, with an IC50 of 1 nM[1].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only. Further protocols information, click here.
Ensayo clínico
| NCT Number | Sponsor | Condition | Start Date |
Phase
|
|---|---|---|---|---|
| NCT01329991 | Plexxikon| | 2011-05 | PHASE1 |
Chemical Information
-
No. CAS 80474-14-2
-
Appearance Solid
-
Peso molecular 500.57
-
Fòrmula C25H31F3O5S
-
Color White to off-white
-
SMILES
O=C(O[C@@]1(C(SCF)=O)[C@](C[C@@H]([C@]([C@@]2(C)C=CC3=O)([C@]4(C[C@@H](C2=C3)F)[H])F)O)(C)[C@]4(C[C@H]1C)[H])CC
-
Envío
Room temperature in continental US; may vary elsewhere.
-
Almacenamiento
Powder -20°C 3 years 4°C 2 years In solvent -80°C 2 years -20°C 1 year
Publications (1)
-
Journal Impact Factor
-
Most Recent
-
J Cachexia Sarcopenia Muscle
A disease-associated missense mutation in CYP4F3 affects the metabolism of leukotriene B4 via disruption of electron transfer. [Abstract]2022 Aug;13(4):2242-2253. PMID: 35686338
Solvente y solubilidad
In Vitro:
DMSO : 100 mg/mL (199.77 mM; Need ultrasonic; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)
H2O : < 0.1 mg/mL (insoluble)
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 2 years; -20°C, 1 year. When stored at -80°C, please use it within 2 years. When stored at -20°C, please use it within 1 year.
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 2 years; -20°C, 1 year. When stored at -80°C, please use it within 2 years. When stored at -20°C, please use it within 1 year.
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
In Vivo:
Select the appropriate dissolution method based on your experimental animal and administration route.
- For the following dissolution methods, please ensure to first prepare a clear stock solution using an In Vitro approach and then sequentially add co-solvents:
- To ensure reliable experimental results, the clarified stock solution can be appropriately stored based on storage conditions. As for the working solution for In Vivo experiments, it is recommended to prepare freshly and use it on the same day.
- The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.
In Vivo Dissolution Calculator
Please enter the basic information of animal experiments:
-
-
-
-
Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.
Please enter your animal formula composition:
-
%DMSO +
Recommended: Keep the proportion of DMSO in working solution below 2% if your animal is weak.
-
%+
-
+%Tween-80 + +
-
%Saline +
The co-solvents required include: DMSO, . All of co-solvents are available by MedChemExpress (MCE). , Tween 80. All of co-solvents are available by MedChemExpress (MCE).
Working solution concentration: 0.22 mg/mL
Method for preparing stock solution: mg drug dissolved in μL DMSO. Stock solution concentration: mg/mL.
1. Take μL DMSO stock solution;
2. Add μL .
μL , mix evenly;
3. Then add μL Tween 80, mix evenly;
4. Then add μL
Please ensure that the stock solution in the first step is dissolved to a clear state, and add co-solvents in sequence. You can use ultrasonic heating (ultrasonic cleaner, recommended frequency 20-40 kHz), vortexing, etc. to assist dissolution.
Protocolo
-
Research Protocol for Endocrine Diseases
Endocrine diseases often arise from disrupted hormone production, hormone signaling, or target-tissue responsiveness; for diabetes-focused endocrine disease models, insulin signaling regulates glucose uptake, hepatic glucose output, lipid metabolism, and β-cell compensation. Type 2 diabetes develops through interacting defects in insulin resistance, β-cell dysfunction, adipose inflammation, hepatic glucose overproduction, altered incretin signaling, and ectopic lipid metabolism. A major unresolved question is whether endocrine dysfunction is driven primarily by target-tissue insulin resistance, intrinsic β-cell failure, immune/inflammatory stress, or combined multi-organ failure that differs by disease stage.
-
Research Protocol for Inflammation-related Diseases
The NLRP3 inflammasome is a cytosolic innate immune signaling platform that integrates priming signals and danger-signal activation to promote caspase-1 activation, maturation of IL-1β and IL-18, and gasdermin D-mediated pyroptotic cell death. The core experimental logic is to determine whether inflammatory disease phenotypes are driven by increased NLRP3 expression, ASC-containing inflammasome assembly, caspase-1 cleavage, GSDMD cleavage, and extracellular release of IL-1β/IL-18 rather than by nonspecific cell injury alone. The pathway is strongly linked to inflammation-related disease phenotypes because monosodium urate crystals activate NALP3/NLRP3 inflammasome signaling in gout-like crystal inflammation, cholesterol crystals activate NLRP3 inflammasomes in atherogenesis models, and DSS-induced intestinal inflammation has been reported to involve NLRP3 inflammasome activity. However, experimental colitis studies also show context-dependent protective effects of NLRP3 inflammasome co
Pureza y Documentación
-
Ficha de datos (277 KB)
-
SDS (393 KB)
- English - EN (393 KB)
- Français - FR (393 KB)
- Deutsch - DE (393 KB)
- Norwegian - NO (393 KB)
- Español - ES (393 KB)
- Swedish - SV (393 KB)
- Italian - IT (393 KB)
- Korean - KR (393 KB)
- Portuguese - PT (393 KB)
-
Instrucciones de manejo (2659 KB)
Referencias
[1]. Bryson HM, et al. Intranasal fluticasone propionate. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic potential in allergic rhinitis. Drugs. 1992;43(5):760-775. [Content Brief]
[2]. Johnson M. The anti-inflammatory profile of fluticasone propionate. Allergy. 1995;50(23 Suppl):11-14. [Content Brief]
[3]. Singanayagam A, et al. Effect of fluticasone propionate on virus-induced airways inflammation and anti-viral immune responses in mice. Lancet. 2015 Feb 26;385 Suppl 1:S88. [Content Brief]
Complete Stock Solution Preparation Table
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 2 years; -20°C, 1 year. When stored at -80°C, please use it within 2 years. When stored at -20°C, please use it within 1 year.
| Optional Solvent | Concentration Solvent Mass | 1 mg | 5 mg | 10 mg | 25 mg |
|---|---|---|---|---|---|
| DMSO | 1 mM | 1.9977 mL | 9.9886 mL | 19.9772 mL | 49.9431 mL |
| 5 mM | 0.3995 mL | 1.9977 mL | 3.9954 mL | 9.9886 mL | |
| 10 mM | 0.1998 mL | 0.9989 mL | 1.9977 mL | 4.9943 mL | |
| 15 mM | 0.1332 mL | 0.6659 mL | 1.3318 mL | 3.3295 mL | |
| 20 mM | 0.0999 mL | 0.4994 mL | 0.9989 mL | 2.4972 mL | |
| 25 mM | 0.0799 mL | 0.3995 mL | 0.7991 mL | 1.9977 mL | |
| 30 mM | 0.0666 mL | 0.3330 mL | 0.6659 mL | 1.6648 mL | |
| 40 mM | 0.0499 mL | 0.2497 mL | 0.4994 mL | 1.2486 mL | |
| 50 mM | 0.0400 mL | 0.1998 mL | 0.3995 mL | 0.9989 mL | |
| 60 mM | 0.0333 mL | 0.1665 mL | 0.3330 mL | 0.8324 mL | |
| 80 mM | 0.0250 mL | 0.1249 mL | 0.2497 mL | 0.6243 mL | |
| 100 mM | 0.0200 mL | 0.0999 mL | 0.1998 mL | 0.4994 mL |
Fluticasone propionate Related Classifications
HY-B0154 Related Classifications
Powered by Bioz